These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 18053672)

  • 1. Control and analysis of alkyl esters of alkyl and aryl sulfonic acids in novel active pharmaceutical ingredients (APIs).
    Elder DP; Teasdale A; Lipczynski AM
    J Pharm Biomed Anal; 2008 Jan; 46(1):1-8. PubMed ID: 18053672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control and analysis of alkyl and benzyl halides and other related reactive organohalides as potential genotoxic impurities in active pharmaceutical ingredients (APIs).
    Elder DP; Lipczynski AM; Teasdale A
    J Pharm Biomed Anal; 2008 Nov; 48(3):497-507. PubMed ID: 18657926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug substances presented as sulfonic acid salts: overview of utility, safety and regulation.
    Elder DP; Snodin DJ
    J Pharm Pharmacol; 2009 Mar; 61(3):269-78. PubMed ID: 19222899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control and analysis of hydrazine, hydrazides and hydrazones--genotoxic impurities in active pharmaceutical ingredients (APIs) and drug products.
    Elder DP; Snodin D; Teasdale A
    J Pharm Biomed Anal; 2011 Apr; 54(5):900-10. PubMed ID: 21145684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A practical derivatization LC/MS approach for determination of trace level alkyl sulfonates and dialkyl sulfates genotoxic impurities in drug substances.
    An J; Sun M; Bai L; Chen T; Liu DQ; Kord A
    J Pharm Biomed Anal; 2008 Nov; 48(3):1006-10. PubMed ID: 18687555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Normal phase and reverse phase HPLC-UV-MS analysis of process impurities for rapamycin analog ABT-578: application to active pharmaceutical ingredient process development.
    Chen Y; Brill GM; Benz NJ; Leanna MR; Dhaon MK; Rasmussen M; Zhou CC; Bruzek JA; Bellettini JR
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Oct; 858(1-2):106-17. PubMed ID: 17826364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of recent applications of flow injection spectrophotometry to pharmaceutical analysis.
    Tzanavaras PD; Themelis DG
    Anal Chim Acta; 2007 Apr; 588(1):1-9. PubMed ID: 17386786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of arylamines and aminopyridines in pharmaceutical products using in-situ derivatization and liquid chromatography-mass spectrometry.
    Vanhoenacker G; Dumont E; David F; Baker A; Sandra P
    J Chromatogr A; 2009 Apr; 1216(16):3563-70. PubMed ID: 18804773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analytical control of genotoxic impurities in the pazopanib hydrochloride manufacturing process.
    Liu DQ; Chen TK; McGuire MA; Kord AS
    J Pharm Biomed Anal; 2009 Sep; 50(2):144-50. PubMed ID: 19427156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Advances on genotoxic impurities of sulfonate esters in pharmaceuticals].
    Liu X; Li C; Han H; Zhang W; Chen D
    Se Pu; 2018 Oct; 36(10):952-961. PubMed ID: 30378353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of methyl and ethyl esters of methanesulfonic, benzenesulfonic and p-toluenesulfonic acids in active pharmaceutical ingredients by solid-phase microextraction (SPME) coupled to GC/SIM-MS.
    Colón I; Richoll SM
    J Pharm Biomed Anal; 2005 Sep; 39(3-4):477-85. PubMed ID: 15950423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analytical methods for residual solvents determination in pharmaceutical products.
    Grodowska K; Parczewski A
    Acta Pol Pharm; 2010; 67(1):13-26. PubMed ID: 20210075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in trace analysis of pharmaceutical genotoxic impurities.
    Liu DQ; Sun M; Kord AS
    J Pharm Biomed Anal; 2010 Apr; 51(5):999-1014. PubMed ID: 20022442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A generic approach for the determination of trace hydrazine in drug substances using in situ derivatization-headspace GC-MS.
    Sun M; Bai L; Liu DQ
    J Pharm Biomed Anal; 2009 Feb; 49(2):529-33. PubMed ID: 19097722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of bisphosphonate active pharmaceutical ingredients in pharmaceuticals and biological material: a review of analytical methods.
    Zacharis CK; Tzanavaras PD
    J Pharm Biomed Anal; 2008 Nov; 48(3):483-96. PubMed ID: 18599247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overall impact of the regulatory requirements for genotoxic impurities on the drug development process.
    Giordani A; Kobel W; Gally HU
    Eur J Pharm Sci; 2011 May; 43(1-2):1-15. PubMed ID: 21420491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trace analysis of per- and polyfluorinated alkyl substances in various matrices-how do current methods perform?
    Jahnke A; Berger U
    J Chromatogr A; 2009 Jan; 1216(3):410-21. PubMed ID: 18817914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Residual solvent analysis in hydrochloride salts of active pharmaceutical ingredients.
    Puranik SB; Pawar VR; Lalitha N; Pai PN; Rao GK
    Pak J Pharm Sci; 2009 Oct; 22(4):410-4. PubMed ID: 19783521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies for the identification, control and determination of genotoxic impurities in drug substances: a pharmaceutical industry perspective.
    Raman NV; Prasad AV; Ratnakar Reddy K
    J Pharm Biomed Anal; 2011 Jun; 55(4):662-7. PubMed ID: 21193280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Residues of genotoxic alkyl mesylates in mesylate salt drug substances: real or imaginary problems?
    Snodin DJ
    Regul Toxicol Pharmacol; 2006 Jun; 45(1):79-90. PubMed ID: 16564608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.